Progress of targeted therapy in diffuse large B-cell lymphoma: reports in the 55th ASH annual meeting / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
; (12): 9-11, 2014.
Article
in Zh
| WPRIM
| ID: wpr-475328
Responsible library:
WPRO
ABSTRACT
With the further study on heterogeneity and molecular mechanism of diffuse large B-cell lymphoma (DLBCL),many novel targeted drugs have been developed,which also showed clinical benefit in early-stage studies.Therapeutic targets for DLBCL mainly include the surface antigens of B lymphocyte,B cell receptor signaling and the cellular microenvironment.Several new clinical trials about targeted therapy for DLBCL had been reported in the 55th ASH annual meeting,and the results were encouraging.The advances in this field will be summarized in this paper based on the new reports in the 55th ASH annual meeting.
Full text:
1
Database:
WPRIM
Language:
Zh
Journal:
Journal of Leukemia & Lymphoma
Year:
2014
Document type:
Article